A reduction in depressive and anxiety symptoms (measured with HADS) was presented in two randomized placebo-controlled studies on dupilumab (a monoclonal antibody binding to IL-4/IL-13 receptors), which may link inflammation and mood disorders in the AD patient population [53,54]. This evidence concerns the gene IL4 and Alzheimer disease.